Two of our picks for 2017, Vuzix Corporation (VUZI) and DarioHealth Corp (DRIO), are on the move.


  • Loading stock data...
  • Loading stock data...

Vuzix Corporation, (web site), a leading supplier of Smart-Glasses, Augmented Reality (AR) and Virtual Reality (VR) technologies and products for the consumer and enterprise markets, announced a significant partnership with Toshiba Client Solutions Co. Ltd., a wholly owned subsidiary of Toshiba Corporation today.

 

This agreement announced today, validates the patented waveguide smart glasses technology held by Vuzix.

In the press release, Carl Pinto, vice president of marketing and product development for Toshiba Client Solutions Division, stated:

“We believe that Toshiba can leapfrog other wearable technology products with Vuzix’ support and look forward to a very successful collaboration between the companies.

and

“We have selected Vuzix as our new smart glasses development and manufacturing partner because we are very impressed with Vuzix’ current line of smart glasses and other technology that the Company has in development.” 

Under the terms of the agreement, Vuzix and Toshiba have embarked on a rapid development program with milestone payments totaling over one million US dollars. With development efforts well under way, Toshiba, subject to a final manufacturing agreement, expects to place additional purchase orders from Vuzix for production deliveries in the 4th quarter of 2017. Further details on the new smart glasses product will be released soon after public marketing of the product commences.

Strong Potential for VUZI Short Squeeze

VUZI can be a volatile stock.  Shorts have been all over it in recent weeks and have now shorted over 25% of the float. With today’s Toshiba announcement, expect more short covering next week, which could lead to the start of a short squeeze if enough new longs as well as covering shorts start hitting the ask.

For a more in-depth look at Vuzix Corporation’s patented technology in the AR space see: Vuzix Corporation (VUZI): New Vuzix Blade 3000 Augmented Reality Glasses a Game-Changer ), presented to subscribers at $6.15/share.

Also see: January 2017 VUZIX Investor Presentation.


dariohealth-logoDarioHealth Corp. (DRIO) has bullish chart pattern going into what will be a record Q4 report.

DarioHealth Corp. (NASDAQ:DRIO), (web site), is a digital health company that develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices.

Its flagship product is the Dario Smart Diabetes Management Solution, a mobile, real-time, cloud-based, diabetes management solution based on a multi-feature software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. DarioHealth Corp. has marketing clearance in Europe and the U.S. and the Dario iOS mobile app recently launched with reimbursement in the United Kingdom, Australia, Israel, Italy, and Canada. Additionally, DarioHealth has launched in New Zealand, the Netherlands, Italy, and Belgium.

 

Nothing drives share prices like strong revenue growth of 282% with more to come. Expect a record Q4 and full year 2016 report to come from DRIO for reasons I explained earlier this week. (see: DarioHealth Corp. (DRIO): Growing Sales By 282% With Record Q4 On Tap.)

DRIO shares are up 10% for the week, and I believe the advance is just beginning. The company only has a float of 2.9 million and can move with very little volume. Every indication points to a continuation of ultra-fast revenue growth as DRIO:

  • Continues rapid expansion in the U.S. market that was only fully underway late last year
  • Launches the Android version of the Smart Glucose Monitoring System
  • Launches in Germany

Bullish DRIO Chart

Technical analysis gurus swear by triple bottom formations as being extremely bullish indicators. DRIO put in a beautiful triple bottom formation as you can see:

With a record Q4 (and another record Q1 in my estimation), plus other near-term positive drivers, I expect to see DRIO shares continue the uptrend they’re now in.

See also:  

 

DarioHealth February 2017 Investor Presentation

Rodman and Renshaw Report: DarioHealth BUY $12 PT

Joseph Gunnar & Co. Report: DarioHealth BUY $8 PT


See: Terms of use/disclosures/disclaimer

Green Organic Dutchman - gary

 

 


 

Leave a reply

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> 

required